Drug Profile


Alternative Names: DS 5565

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Acetic acids; Analgesics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuropathic pain; Pain; Postherpetic neuralgia

Most Recent Events

  • 01 Mar 2017 Daiichi Sankyo completes a phase III trial for Postherpetic neuralgia and Neuropathic pain (in patients with diabetic peripheral neuropathy and renal impairment) in Japan (PO) (NCT02607280)
  • 12 Jan 2017 Daiichi Sankyo completes a phase III trial for Pain associated with fibromyalgia in USA, Austria, Argentina, Belarus, Belgium, Chile, Colombia, Israel, Mexico, Poland, Portugal, Slovenia, Spain, Switzerland (NCT02187471)
  • 26 Sep 2016 Efficacy and safety data from a phase II trial in Neuropathic pain presented at the 16th World Congress on Pain (PAN-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top